The Moderate to Severe Atopic Dermatitis (AD) Market is set to witness immense growth during the forecast period 2022-2028. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufacturers/players/vendors analysis, segments & sub-segments, and forecast. The report also focuses on market drivers, challenges (current and future), revenue growth, future roadmap, standardization, deployment models, and forecast analysis.
Overview:
Atopic dermatitis usually begins on the face, arms, legs, and/or scalp and can progress to other body parts. It is characterized by severe itching and blisters that develop on the affected area. As a child grows, the rash can extend to other areas of the body, such as the elbows, eyelids, and genitals. Severe itching may occur before the rash develops. In the majority of cases, atopic dermatitis is a lifelong condition. Symptoms may persist into adulthood, and treatment can help control the disease. Most people can control the occurrence of flare-ups. If diagnosed in its early stages, treatment will help control the condition. Most children will grow out of the condition by the time they reach their teenage years, but some will continue to suffer from the symptoms as adults. In addition to dermatologic therapy, topical medications may help alleviate the symptoms of atopic dermatitis. There are creams, lotions, and bath oils available for the treatment of atopic dermatitis. In some cases, antihistamines may be prescribed as well. In addition to treating eczema, medications may also be prescribed for children with atopic dermatitis.
The global moderate to severe atopic dermatitis (AD) market focuses on six regions, such as North America, Asia Pacific, South America, Europe, the Middle East, and Africa.
Drivers:
The increasing incidence of atopic dermatitis in the world is expected to fuel the growth of the global moderate to severe atopic dermatitis (AD) market over the forecast period. For instance, according to ScienceDirect, atopic dermatitis affects around 2.4% of the global population. While the physical effects of eczema are easy to see, the emotional effects are not as noticeable. Children who have atopic dermatitis may feel isolated. They may be unable to participate in important activities, and this can negatively impact their family life. In addition, inadequate sleep can affect their academic and social lives. So, when patients are diagnosed with eczema, it's important to visit a dermatologist. Increasing treatment launches by key market players are estimated to enhance the growth of the global moderate to severe atopic dermatitis (AD) market.
Restraints:
Less awareness related to atopic dermatitis is expected to hinder the growth of the global moderate to severe atopic dermatitis (AD) market.
Regional Insights:
In regions, North America is expected to hold a major share of the global moderate to severe atopic dermatitis (AD) market, owing to the increasing prevalence of the disease in the region. For instance, according to the United States National Institutes of Health (NIH), around 16.5 million individuals in the United States suffer from atopic dermatitis. Moreover, the Asia Pacific is estimated to witness significant growth in the global moderate to severe atopic dermatitis (AD) market owing to the increasing expansion of healthcare facilities in the region.
Competitive Section:
Key players operating in the global moderate to severe atopic dermatitis (AD) market include Evelo Biosciences Inc., Regeneron Pharmaceuticals Inc., Bristol Myers Squibb, Abbvie Inc., and Pfizer Inc.
Moderate to Severe Atopic Dermatitis (AD) Market Dynamics:
This market study estimates the market size in terms of both value (million USD) and volume (K Units). The Moderate to Severe Atopic Dermatitis (AD) Market report analyses market trends based on historical data and the latest developments. It provides both qualitative and quantitative data on the elements that will shape the market's growth from 2022 to 2028. The market capacity and consumption potential of major companies are discussed in this research report. Furthermore, it concentrates on prominent regions (Latin America, Europe, Asia Pacific, Africa, and the Middle East). Also, the report evaluates COVID-19's impact on the Moderate to Severe Atopic Dermatitis (AD) Market.
Companies profiled in the Moderate to Severe Atopic Dermatitis (AD) Market report include:
- Pfizer Inc.
- Abbvie Inc.
- Bristol Myers Squibb
- Regeneron Pharmaceuticals Inc.
- Evelo Biosciences Inc.
The report covers extensive competitive intelligence which includes the following data points:
⇨ Business Overview
⇨ Business Model
⇨ Financial Data
⇨ Financial – Existing
⇨ Financial – Funding
⇨ Product/Service Segment Analysis and specification
⇨ Recent Development and Company Strategy Analysis
⇨ SWOT Analysis
Segmentation by Type:
The type segment contributed the largest share to the Moderate to Severe Atopic Dermatitis (AD) Market in 2021; this segment is projected to grow at the highest CAGR from 2022 to 2028.
- Drug Treatment
- Radiation Treatment
Segmentation by Application:
An end-use industry is projected to grow at the highest CAGR during the forecast period, due to rapid development in emerging economies North America, APAC, MEA, Europe, and ROW.
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
- Mail Order Pharmacies
- Dermatology Clinics
Key Benefits for Stakeholders:
- The study represents a quantitative analysis of the present Moderate to Severe Atopic Dermatitis (AD) Market trends, estimations, and dynamics of the market size from 2022 to 2028 to determine the most promising opportunities.
- Porter's five forces study emphasizes the importance of buyers and suppliers in assisting stakeholders to make profitable business decisions and expand their supplier-buyer network.
- In-depth analysis, as well as market size and segmentation, help you identify current Moderate to Severe Atopic Dermatitis (AD) Market opportunities.
- The largest countries in each region are mapped according to their revenue contribution to the market.
- The Moderate to Severe Atopic Dermatitis (AD) Market research report gives a thorough analysis of the current status of the Moderate to Severe Atopic Dermatitis (AD) Market's major players.
Reasons to Purchase Moderate to Severe Atopic Dermatitis (AD) Market Report:
- Both current and future prospects for the Moderate to Severe Atopic Dermatitis (AD) Market in developed and emerging markets.
- Analysis of various perspectives of the market with the help of Porter’s five forces analysis.
- During the forecast period, major regions are expected to see the most rapid increase.
- Identify the most recent advancements, Moderate to Severe Atopic Dermatitis (AD) Market shares, and top market players' strategies.
Research Methodology:
To estimate and validate the size of the Moderate to Severe Atopic Dermatitis (AD) Market and many other dependent submarkets in the overall market, both top-down and bottom-up methodologies are utilized. Key players in the market have been identified through secondary research and their market shares have been determined through primary and secondary research. Secondary sources and verified primary sources were used to determine all percentage share splits and breakdowns.
Request Discount 
Inquire Before Buy
